Zai Lab Ltd (ZLAB)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$23.51

+1.01 (+4.49%)

Market Cap: $2.53B

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

54%(19/35)

Avg Surprise

-0.63%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.56

Range$-0.67 - $-0.49

6 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$-0.53-7.1%

60d ago$-0.53-7.1%

30d ago$-0.54-5.4%

7d ago$-0.58+2.1%

Current$-0.56

Revenue Consensus

$109M

Range$105M - $112M

6 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.42

Range$-0.98 - $0.17

10 analysts

Revenue Consensus

$121M

Range$95M - $173M

14 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.42	$-0.98 - $0.17	-	-	10	-	-
Sep 30, 2026Sep 26EST	-	$-0.56	$-0.67 - $-0.49	-	-	6	2 3 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-0.46	$-0.66	$-0.99 - $-0.58	+30.30%	Beat	6	0 4 30d	-24.3%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-0.46	$-0.29	$-0.34 - $-0.22	-58.13%	Miss	5	0 3 30d	-2.2%
Dec 31, 2025Dec 25 Reported Feb 26, 2026Reported Feb 26	$-0.46	$-0.44	$-0.75 - $-0.22	-4.55%	Miss	6	1 2 30d	+42.5%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$-0.33	$-0.29	$-0.37 - $-0.21	-13.79%	Miss	6	0 2 30d	+21.4%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-0.37	$-0.37	$-0.56 - $-0.35	+0.00%	Beat	6	1 1 30d	+54.9%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$-0.45	$-0.55	$-0.69 - $-0.47	+18.18%	Beat	5	No revisions (30d)	+10.0%
Dec 31, 2024Dec 24 Reported Feb 27, 2025Reported Feb 27	$-0.80	$-0.63	$-0.72 - $-0.48	-26.32%	Miss	5	2 0 30d	+18.4%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-0.42	$-0.78	$-0.90 - $-0.68	+46.15%	Beat	6	1 0 30d	+40.8%
Jun 30, 2024Jun 24 Reported Aug 6, 2024Reported Aug 6	$-0.82	$-0.73	$-0.85 - $-0.59	-12.33%	Miss	6	No revisions (30d)	+34.4%
Mar 31, 2024Mar 24 Reported May 8, 2024Reported May 8	$-0.50	$-0.92	$-1.09 - $-0.75	+45.65%	Beat	6	1 0 30d	+2.0%
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$-0.98	$-0.87	$-0.97 - $-0.78	-12.64%	Miss	6	No revisions (30d)	-50.8%
Sep 30, 2023Sep 23 Reported Nov 7, 2023Reported Nov 7	$-0.71	$-1.03	$-1.25 - $-0.71	+31.07%	Beat	6	0 2 30d	+57.7%
Jun 30, 2023Jun 23 Reported Aug 7, 2023Reported Aug 7	$-1.25	$-0.81	$-1.04 - $-0.66	-54.32%	Miss	5	No revisions (30d)	+13.2%
Mar 31, 2023Mar 23 Reported May 9, 2023Reported May 9	$-0.51	$-0.97	$-1.05 - $-0.86	+47.42%	Beat	5	1 0 30d	+40.7%
Dec 31, 2022Dec 22 Reported Feb 28, 2023Reported Feb 28	$-0.65	$-1.11	$-1.33 - $-1.01	+41.44%	Beat	5	No revisions (30d)	+70.0%
Sep 30, 2022Sep 22 Reported Nov 9, 2022Reported Nov 9	$-1.68	$-1.25	$-1.68 - $-0.20	-34.40%	Miss	5	No revisions (30d)	-66.3%
Jun 30, 2022Jun 22 Reported Aug 9, 2022Reported Aug 9	$-1.44	$-1.07	$-1.44 - $-0.93	-34.58%	Miss	4	No revisions (30d)	+18.2%
Mar 31, 2022Mar 22 Reported May 10, 2022Reported May 10	$-0.86	$-1.23	$-1.23 - $-1.23	+30.08%	Beat	4	No revisions (30d)	+67.4%
Dec 31, 2021Dec 21 Reported Mar 1, 2022Reported Mar 1	$-2.17	$-1.33	$-2.25 - $-0.24	-63.16%	Miss	10	0 2 30d	-445.0%
Sep 30, 2021Sep 21 Reported Nov 9, 2021Reported Nov 9	$-1.01	$-1.27	$-1.74 - $-1.01	+20.47%	Beat	5	No revisions (30d)	-153.6%
Jun 30, 2021Jun 21 Reported Aug 9, 2021Reported Aug 9	$-1.76	$-1.39	$-1.76 - $-1.33	-26.62%	Miss	4	No revisions (30d)	-162.7%
Mar 31, 2021Mar 21 Reported May 10, 2021Reported May 10	$-2.64	$-2.30	$-2.30 - $-0.86	-14.78%	Miss	2	No revisions (30d)	-166.7%
Dec 31, 2020Dec 20 Reported Mar 1, 2021Reported Mar 1	$-0.40	N/A	-	+59.78%	Beat	0	No revisions (30d)	+41.4%
Sep 30, 2020Sep 20 Reported Dec 2, 2020Reported Dec 2	$-0.40	$-0.40	-	+0.45%	Beat	-	-	+33.1%
Jun 30, 2020Jun 20 Reported Aug 13, 2020Reported Aug 13	$-0.67	$-0.99	$-0.99 - $-0.99	+32.32%	Beat	0	No revisions (30d)	-55.8%
Mar 31, 2020Mar 20 Reported Jun 3, 2020Reported Jun 3	$-0.99	$-0.99	$-0.99 - $-0.99	+0.01%	Beat	0	No revisions (30d)	-47.4%
Dec 31, 2019Dec 19 Reported Jan 21, 2020Reported Jan 21	$-0.68	$-0.60	$-0.60 - $-0.60	-13.33%	Miss	1	1 0 30d	+0.0%
Sep 30, 2019Sep 19 Reported Nov 27, 2019Reported Nov 27	$-0.60	$-0.60	-	+0.78%	Beat	-	-	-80.4%
Jun 30, 2019Jun 19 Reported Sep 3, 2019Reported Sep 3	$-0.43	$-0.67	-	+35.82%	Beat	-	-	-65.4%
Mar 31, 2019Mar 19 Reported May 29, 2019Reported May 29	$-0.67	$-0.44	-	-52.66%	Miss	-	-	-168.7%
Dec 31, 2018Dec 18 Reported Mar 7, 2019Reported Mar 7	$-0.68	$-0.45	-	-51.11%	Miss	0	No revisions (30d)	+82.8%
Sep 30, 2018Sep 18 Reported Nov 28, 2018Reported Nov 28	$-0.33	$-0.40	-	+17.50%	Beat	-	-	-57.1%
Jun 30, 2018Jun 18 Reported Aug 30, 2018Reported Aug 30	$-0.26	$-0.38	-	+31.58%	Beat	-	-	+65.1%
Mar 31, 2018Mar 18 Reported May 2, 2018Reported May 2	$-0.25	$-0.17	-	-47.06%	Miss	-	-	+97.8%
Dec 31, 2017Dec 17 Reported Dec 31, 2017Reported Dec 31	$-3.95	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-419.6%
Sep 30, 2017Sep 17 Reported Nov 15, 2017Reported Nov 15	$-0.21	$-0.23	$-0.23 - $-0.23	+8.70%	Beat	0	No revisions (30d)	-
Jun 30, 2017Jun 17 Reported Sep 21, 2017Reported Sep 21	$-0.74	N/A	-	N/A	Beat	-	-	-
Mar 31, 2017Mar 17 Reported Mar 31, 2017Reported Mar 31	$-11.49	N/A	-	N/A	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Mar 30, 2017Reported Mar 30	$-0.76	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-13.75	EV/EBITDA	N/A
Price/FCF	-16.16x	FCF Yield	-6.19%
Profitability
Profit Margin	-41.90%	Operating Margin	-72.00%
ROE	-26.90%	ROIC	-21.57%
Financial Health
Debt/Equity	0.39x	Interest Coverage	-30.87x
Current Ratio	2.13x	Quick Ratio	1.92x
Trading Statistics
Beta	0.72	Avg Volume	800.39K
52-Week High	$29.77	52-Week Low	$15.96

Technical Indicators Dashboard

Moving Averages

SMA 10$24.43

SMA 20$25.15

SMA 50$25.28

SMA 200$20.70

EMA 10$24.21

EMA 20$24.69

EMA 50$24.29

EMA 200$22.82

MACD

Line: -0.39Signal: -0.06Hist: -0.34

ADX

ADX: 15.0+DI: 31.2-DI: 34.7

Aroon & PSAR

Aroon Up24.0

Aroon Down96.0

PSAR$26.27

Bollinger Bands

Upper Band$27.36

Lower Band$22.94

%B Position1755%(Upper)

Band Width0.13

RSI (14-Day)

Neutral

42.2

Momentum Oscillators

Stoch %K14.9

Stoch %D17.9

Williams %R-71.0

ROC (10d)-7.8%

Momentum-1.99

CCI (20d)-134.2

MFI (14d)56.7

Volatility Measures

ATR (14d)$1.17(5.0%)

StdDev (20d)1.10

Hist Vol47.2%(High)

Volume Flow

VWAP$23.46

OBV-21.5M

AD Line-4.0M

CMF (20d)-0.155

Volume Metrics

Avg Vol (20d)788.9K

Vol Ratio1.0x

VWMA (20d)$25.19

Pivot Points

R3$23.51

R2$23.15

R1$22.83

Pivot Point$22.47

S1$22.15

S2$21.79

S3$21.47

Advanced Oscillators

TSI-9.76

Ultimate Osc45.2

KST-39.15

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$106.31M	$99.61M	$127.60M	$116.09M	$109.98M	$106.49M	$109.07M	$102.27M	$100.50M	$87.15M	$65.83M	$69.23M
Cost of Revenue	$48.16M	$38.34M	$62.33M	$46.88M	$43.22M	$38.65M	$42.09M	$36.92M	$35.23M	$33.62M	$25.24M	$25.48M
Gross Profit	$58.15M	$61.28M	$65.27M	$69.21M	$66.76M	$67.84M	$66.98M	$65.35M	$65.27M	$53.53M	$40.59M	$43.75M

Operating Expenses	$134.64M	$130.56M	$134.67M	$118.03M	$121.65M	$124.15M	$134.87M	$133.20M	$141.34M	$123.84M	$164.57M	$127.32M
R&D	$61.77M	$65.59M	$61.63M	$47.93M	$50.61M	$60.73M	$52.25M	$65.98M	$61.63M	$54.65M	$81.95M	$58.77M
SG&A	$72.87M	$65.07M	$73.04M	$41.32M	$42.68M	$63.42M	$82.62M	$67.22M	$79.71M	$69.19M	$82.63M	$68.55M
Operating Income	$-76,489,000	$-69,279,000	$-69,406,000	$-48,822,000	$-54,895,000	$-56,311,000	$-67,891,000	$-67,853,000	$-76,064,000	$-70,309,000	$-123,981,000	$-83,570,000

Interest Income	$5.88M	$6.45M	$7.25M	$8.35M	$8.84M	$8.61M	$9.09M	$9.03M	$9.33M	$9.66M	$10.30M	$9.17M
Interest Expense	$1.59M	$1.64M	$1.36M	$1.40M	$1.26M	$1.19M	$904,000	$745,000	$492,000	$113,000	$20.38M	$0
Income Before Tax	$-51,847,000	$-49,576,000	$-53,336,000	$-35,963,000	$-40,727,000	$-48,438,000	$-81,684,000	$-41,671,000	$-80,277,000	$-53,471,000	$-95,429,000	$-69,152,000
Income Tax Expense	$-1,022,000	$1.44M	$-2,927,000	$0	$0	$0	$0	$0	$0	$9.47M	$-21,769,000	$-9,172,000

Net Income	$-50,825,000	$-51,016,000	$-50,409,000	$-35,963,000	$-40,727,000	$-48,438,000	$-81,684,000	$-41,671,000	$-80,277,000	$-53,471,000	$-95,429,000	$-69,152,000

EBITDA	$-46,087,000	$-43,995,000	$-48,059,000	$-30,662,000	$-35,730,000	$-43,793,000	$-77,748,000	$-38,055,000	$-76,844,000	$-50,346,000	$-119,089,000	$-67,234,000
EBIT	$-50,260,000	$-47,939,000	$-51,975,000	$-34,563,000	$-39,465,000	$-47,251,000	$-80,780,000	$-40,926,000	$-79,785,000	$-53,358,000	$-121,548,000	$-69,152,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about ZLAB

News

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Zai Lab announced it will present data from its first clinical trial of ZL-1503, an IL-13/IL-31Rα bispecific antibody...

Yahoo Finance•Oct 14, 2026 7:10 AM ET10/14/26•Bullish

Current ratio of Zai Lab Ltd. – HAM:1ZLB

This article provides financial information for Zai Lab Ltd. (HAM:1ZLB), specifically focusing on its current ratio. The content lists the period, value...

TradingView•Oct 12, 2026 2:11 AM ET10/12/26•Neutral

Zai Lab (ZLAB) Sets Up ESMO Data Debut, Is The Stock Still Cheap?

Zai Lab (ZLAB) is gaining attention as it prepares to present global Phase 1b/1c data for its lung cancer drug zocilurtatug pelitecan at the 2026 ESMO Congress. Despite recent stock momentum...

Simply Wall Street•Oct 11, 2026 9:39 AM ET10/11/26•Somewhat-Bullish

Did Trial Data Debut Just Shift Zai Lab (ZLAB) Stock Narrative?

Zai Lab's investment narrative is shifting due to the upcoming presentation of global Phase 1b/1c data for its DLL3-targeting antibody drug conjugate zocilurtatug pelitecan at ESMO 2026. While this proprietary oncology...

Simply Wall Street•Oct 8, 2026 7:40 AM ET10/8/26•Neutral

Did Trial Data Debut Just Shift Zai Lab (ZLAB) Stock Narrative?

Zai Lab is scheduled to present Phase 1b/1c trial data for its DLL3-targeting antibody drug conjugate, zocilurtatug pelitecan...

Simply Wall Street•Oct 8, 2026 7:34 AM ET10/8/26•Neutral

ZLAB Valuation and Fair Value

P/E: -13.7x
P/FCF: -16.2x
P/B: 4.3x

See GNG's fair value

ZLAB Profitability: Margins, ROIC and FCF

Gross margin: 56.5%
Operating margin: -72.0%
Net margin: -41.9%
ROIC: -21.6%
ROE: -26.9%
FCF margin: -36.1%
FCF yield: -6.2%

ZLAB Competitors

Company	Ticker
Clover Health Investments Corp	CLOV
Sellas Life Sciences Group Inc	SLS
Guardian Pharmacy Services, Inc.	GRDN
Beam Therapeutics Inc	BEAM
Nurix Therapeutics Inc	NRIX
Maravai Lifesciences Holdings Inc	MRVI
TransMedics Group Inc	TMDX
MBX Biosciences, Inc. Common Stock	MBX

Sector: Healthcare

ZLAB Analyst Ratings

Consensus: Buy
Analysts: 12
Strong Buy: 2
Buy: 9
Hold: 1
Sell: 0
Strong Sell: 0

ZLAB Bull Case vs Bear Case

Bull case

91.7% of ZLAB's analyst ratings are Buy or Strong Buy.

Bear case

ZLAB has a -41.9% net profit margin.
ZLAB beat EPS estimates in 37.5% of its last 8 reported quarters.
ZLAB's quarterly revenue changed -3.3% year over year.

ZLAB Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -1.0%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.56
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 2 up, 3 down

Frequently Asked Questions About ZLAB

Does ZLAB pay dividends?

Zai Lab Ltd (ZLAB) does not currently pay a regular dividend.

What is ZLAB's market cap?

Zai Lab Ltd (ZLAB) has a market capitalization of $2.53B with a current stock price of $23.51.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In

Earnings

Performance (10Y)

Upcoming Estimates

Key Metrics

Technical Indicators Dashboard

Moving Averages

MACD

ADX

Aroon & PSAR

Bollinger Bands

RSI (14-Day)

Momentum Oscillators

Volatility Measures

Volume Flow

Volume Metrics

Pivot Points

Advanced Oscillators

Financial Data

Related GNG Research

News

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Current ratio of Zai Lab Ltd. – HAM:1ZLB

Zai Lab (ZLAB) Sets Up ESMO Data Debut, Is The Stock Still Cheap?

Did Trial Data Debut Just Shift Zai Lab (ZLAB) Stock Narrative?

Did Trial Data Debut Just Shift Zai Lab (ZLAB) Stock Narrative?

ZLAB Valuation and Fair Value

ZLAB Profitability: Margins, ROIC and FCF

ZLAB Competitors

ZLAB Analyst Ratings

ZLAB Bull Case vs Bear Case

Bull case

Bear case

ZLAB Earnings: Beat Rate and Next Report

Frequently Asked Questions About ZLAB

Related stocks

Get full access to GNG Research